Free Trial

Zacks Research Brokers Boost Earnings Estimates for PBH

Prestige Consumer Healthcare logo with Medical background

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Stock analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, June 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.19 per share for the quarter, up from their previous forecast of $1.18. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.73 EPS and Q4 2027 earnings at $1.25 EPS.

Other analysts also recently issued reports about the company. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Check Out Our Latest Research Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.27 during trading on Wednesday, hitting $83.37. The stock had a trading volume of 362,361 shares, compared to its average volume of 298,971. The company has a 50 day moving average price of $83.93 and a 200-day moving average price of $82.51. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of 19.43, a P/E/G ratio of 2.50 and a beta of 0.45. Prestige Consumer Healthcare has a one year low of $64.94 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The firm's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 EPS.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kestra Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $27,000. CIBC Private Wealth Group LLC raised its holdings in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the 1st quarter worth $38,000. Headlands Technologies LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $40,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Recommended Stories

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?

Before you consider Prestige Consumer Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.

While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines